J&J brain drug acquired in $14.6B buyout cleared for broader use

<figure><div><img src="https://imgproxy.divecdn.com/UIqL1OmUDsLl_jtLkdamoZaCE4pUwVypTaRjsOC7bzE/g:nowe:0:0/c:1732:978/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMzczMjYxMzY1LmpwZw==.webp" /></div></figure><p>Caplyta, which J&amp;J got in its acquisition of Intra-Cellular Therapies, netted a clearance in major depressive disorder that&rsquo;s key to achieving the $5 billion in annualized sales the company expects.</p>